[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635754":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":34,"centralContacts":40,"locations":49,"responsibleParty":71,"collaborators":34,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":34,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":34,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":34,"overallStatus":92,"whyStopped":34,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY",[8,14,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"IBI3016 dose 4","EXPERIMENTAL","subcutaneous injection",[13],"Drug: IBI3016",{"label":15,"type":10,"description":11,"interventionNames":16},"IBI3016 dose 3",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"IBI3016 dose 2",[13],{"label":21,"type":10,"description":11,"interventionNames":22},"IBI3016 dose 1",[13],{"label":24,"type":25,"description":11,"interventionNames":26},"placebo","PLACEBO_COMPARATOR",[27],"Other: Placebo",[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","IBI3016","Solution of Injection",[21,18,15,9],null,{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":34},"OTHER","Placebo","0.9% sodium chloride saline solution",[24],[41,46],{"name":42,"role":43,"phone":44,"phoneExt":34,"email":45},"Andy Guo","CONTACT","0512-69566088","andy.guo@innoventbio.com",{"name":47,"role":43,"phone":44,"phoneExt":34,"email":48},"Jinling Fan","jinling.fan@innoventbio.com",[50],{"facility":51,"status":34,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Beijing Anzhen Hospital, Capital Medical University","Beijing","Beijing Municipality","100029","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64,68],{"name":65,"role":43,"phone":66,"phoneExt":34,"email":67},"yang lin","010-81992130","linyang3623@163.com",{"name":69,"role":43,"phone":66,"phoneExt":34,"email":70},"shan Jing","jingshan@anzhengcp.com",{"type":72,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100635754","phase-1-study-of-ibi3016-in-people-with-mild-or-moderate-hypertension-patients-100635754",false,"NCT07556796","Study of IBI3016 in People With Mild or Moderate Hypertension Patients","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Features of a Single Subcutaneous Administration of IBI3016 in Patients With Mild or Moderate Hypertension in China","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Males or females aged 18 to 75 years. 3 Diagnosed primary hypertension who have not been taking anti-hypertensive medication within 4 weeks prior to informed consent.\n\n4.Mean sitting SBP ≥140 mmHg and \\\u003C 170 mmHg measured by OBPM. 5.Participants able to understand and comply with study procedures.\n\nExclusion Criteria:\n\n1. Known history of secondary hypertension.\n2. Orthostatic hypotension.\n3. Laboratory parameter assessments outside of range at screening：\n\n   * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \\> 2× Upper Limit of Normal (ULN)\n   * Total Bilirubin \\> 1.5× ULN\n   * International Normalized Ratio (INR) \\> 2.0\n   * Serum Potassium \\> 5 mmol\u002FL\n   * Estimated Glomerular Filtration Rate (eGFR) ≤ 45 mL\u002Fmin\u002F1.73m²\n   * QTcF \\> 480 ms\n4. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.\n5. Current or history of intolerance to ACEi and\u002For ARBs.\n6. Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening, or a previous diagnosis of decompensated heart failure or New York Heart Association (NYHA) grade III or IV heart failure.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years","75 Years",{"count":84,"type":85},30,"ESTIMATED","INTERVENTIONAL",[88],"PHASE1","A Phase I clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and pharmacodynamic characteristics of a single subcutaneous dose of IBI3016 in Chinese patients with mild to moderate hypertension.",[91],"Hypertension","NOT_YET_RECRUITING","2026-04-22",{"date":95,"type":96},"2026-04-29","ACTUAL",{"date":98,"type":85},"2026-05-15",{"date":100,"type":85},"2027-10-16",{"name":5,"class":6},1]